• 1
    Chuang YC, Sheng WH, Li SY et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011; 52: 352360.
  • 2
    Lee YC, Huang YT, Tan CK et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66: 18391846.
  • 3
    Nemec A, Krizova L, Maixnerova M et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 2011; 162: 393404.
  • 4
    Chiang MC, Kuo SC, Chen SJ et al. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2011; 40: 1926.
  • 5
    Lee NY, Chang TC, Wu CJ et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010; 61: 219227.
  • 6
    Anatoliotaki M, Valatas V, Mantadakis E et al. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection 2004; 32: 6571.
  • 7
    Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34: 580584.
  • 8
    Liang-Yu C, Kuo SC, Liu CY et al. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997–2007. J Microbiol Immunol Infect 2011; 44: 358363.
  • 9
    Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang TC. Species-level identification of isolates of the Acinetobacter calcoaceticusAcinetobacter baumannii complex by sequence analysis of the 16S–23S rRNA gene spacer region. J Clin Microbiol 2005; 43: 16321639.
  • 10
    Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. CLSI Document M100-S21. Wayne, PA: CLSI, 2011.
  • 11
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128140.
  • 12
    Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268281.
  • 13
    Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Goncalves VM. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur J Clin Microbiol Infect Dis 2006; 25: 17.
  • 14
    Kwon KT, Oh WS, Song JH et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525530.
  • 15
    Gudiol C, Calatayud L, Garcia-Vidal C et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65: 333341.